SHOOL OF PHARMACY

PHARMACEUTICAL ANALYSIS ASSIGNMENT I

NAME BELAYNEH MATHEWOS ……………UGR/8952/12

SUBMITTED TO : INSTRUCTOR MINICHIL C.

DATE OF SUBMISSION: Nov 05,2021
Browse: British Pharmacopoeia 2009
British Pharmacopoeia Volume I & II
Monographs: Medicinal and Pharmaceutical Substances
Bumetanide
Bumetanide
General Notices
(Ph Eur monograph 1076)

C17H20N2O5Sıı364.4ıı28395-03-1
Action and use
Loop diuretic.
Preparations
Bumetanide Injection
Bumetanide Oral Solution
Bumetanide Tablets
Bumetanide and Slow Potassium Tablets

DEFINITION
3-(Butylamino)-4-phenoxy-5-sulphamoylbenzoic acid.
Content
99.0 per cent to 101.0 per cent (dried substance).
CHARACTERS
Appearance
White or almost white, crystalline powder.

Solubility

Practically insoluble in water, soluble in acetone and in alcohol, slightly soluble

in methylene chloride. It dissolves in dilute solutions of alkali hydroxides.It
shows polymorphism (5.9).

mp
About 233 °C.

IDENTIFICATION
Infrared absorption spectrophotometry (2.2.24).
Comparisonıbumetanide CRS.
If the spectra obtained in the solid state show differences, dissolve the substance
to be
examined and the reference substance separately in acetone R, evaporate to
dryness and record new spectra using the residues.
TESTS
Appearance of solution
The solution is clear (2.2.1) and colourless (2.2.2, Method II).
Dissolve 0.1 g in a 6 g/l solution of potassium hydroxide R and dilute to 20 ml with
the same solution.
Related substances
Liquid chromatography (2.2.29).
Test solutionıDissolve 50 mg of the substance to be examined in the mobile phase
and dilute to 25.0 ml with the mobile phase.
Reference solution (a)ıDilute 1.0 ml of the test solution to 100.0 ml with the
mobile phase.
Dilute 1.0 ml of this solution to 10.0 ml with the mobile phase.
Reference solution (b)ıDissolve 2 mg of bumetanide impurity A CRS and 2 mg of
bumetanide impurity B CRS in the mobile phase and dilute to 10.0 ml with the
mobile phase.
Dilute 1.0 ml of this solution to 100.0 ml with the mobile phase.
Column:ı
ı— size: l = 0.15 m, Ø = 4.6 mm,
ı— stationary phase: end-capped octylsilyl silica gel for chromatography R (3.5
μm).
Mobile phaseıMix 70 volumes of methanol R, 25 volumes of water for
chromatography R and 5 volumes of a 27.2 g/l solution of potassium dihydrogen
phosphate R previously adjusted to pH 7.0 with a 280 g/l solution of potassium
hydroxide R; add tetrahexylammonium bromide R to this mixture to obtain a
concentration of 2.17 g/l.
Flow rateı1.0 ml/min.
DetectionıSpectrophotometer at 254 nm.
Injectionı10 μl.
Run timeı5 times the retention time of bumetanide.
Relative retentionıWith reference to bumetanide (retention time = about 6 min):
impurity B = about 0.4; impurity A = about 0.6; impurity D = about 2.5; impurity C
= about 4.4.
System suitabilityıReference solution (b):
ı— resolution: minimum 2.0 between the peaks due to impurity A and impurity B.
Limits:
ı— impurities A, B, C, D: for each impurity, not more than the area of the
principal peak in
the chromatogram obtained with reference solution (a) (0.1 per cent),
ı— other impurities: for each impurity, not more than the area of the principal
peak in the
chromatogram obtained with reference solution (a) (0.1 per cent),
ı— total: not more than twice the area of the principal peak in the chromatogram
obtained
with reference solution (a) (0.2 per cent),
ı— disregard limit: 0.5 times the area of the principal peak in the chromatogram
obtained
with reference solution (a) (0.05 per cent).
Loss on drying (2.2.32)
Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C for 4
h.
Sulphated ash (2.4.14)
Maximum 0.1 per cent, determined on 1.0 g.
ASSAY
Dissolve 0.300 g in 50 ml of alcohol R. Add 0.1 ml of phenol red solution R. Titrate
with 0.1 M
sodium hydroxide until a violet-red colour is obtained. Carry out a blank
titration.
1 ml of 0.1 M sodium hydroxide is equivalent to 36.44 mg of C17H20N2O5S.

STORAGE
Protected from light.
IMPURITIES
Specified impuritiesıA, B, C, D.

ıA. R1 = H, R2 = NO2: 3-nitro-4-phenoxy-5-sulphamoylbenzoic acid,

ıB. R1 = H, R2 = NH2: 3-amino-4-phenoxy-5-sulphamoylbenzoic acid,
ıC. R1 = C4H9, R2 = NH-C4H9: butyl
3-(butylamino)-4-phenoxy-5-sulphamoylbenzoate,
ıD. 3-[[(2RS)-2-ethylhexyl]amino]-4-phenoxy-5-sulphamoylbenzoic acid.